Brainsway Ltd. reported that it has completed an additional $6 million investment in Neurolief Ltd. after the FDA approved the Proliv™Rx system for major depressive disorder (MDD) on March 26, 2026. This filing is significant for investors as it indicates strategic expansion in their partnership.